← Russell 3000 cross-section

GDRX GoodRx Holdings, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Technology

Scale

Market cap
$1.2bn
Revenue TTM
$785m
Net income TTM
$16m
Free cash flow
$197m
Composite score
55.9
Sector rank
#1931

Valuation

P / E
73.0
EV / EBITDA
EV / sales
1.7
FCF yield
16.63%
Earnings yield vs 10-yr
-3.36pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
2.1%
EBITDA margin
ROE
2.5%
ROIC
9.0%
Revenue growth
-1.8%

Insider activity, last 90 days

Net open-market
$-9.68m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

As an extension of the changing retail pharmacy landscape, we have seen and continue to expect heightened renegotiations between pharmacies and PBMs, including changes in retailer reimbursement models, as a result of the pharmacies' increased focus on rationalizing their spending. These external factors have adversely impacted our prescription transactions revenue, financial results, and Monthly Active Consumers, all of which we expect will continue in the near term and are reflected in our year-over-year comparative results below . …GoodRx Holdings, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →